303 related articles for article (PubMed ID: 19114876)
1. Incidence of new stroke or new myocardial infarction or death at 39-month follow up in patients with diabetes mellitus, hypertension, or both treated with and without angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
Ravipati G; Aronow WS; Ahn C; Alappat RM; McClung JA; Weiss MB
Am J Ther; 2009; 16(1):2-4. PubMed ID: 19114876
[TBL] [Abstract][Full Text] [Related]
2. Incidence of new stroke or new myocardial infarction or death at 39-month follow-up in patients with diabetes mellitus, hypertension or both with and without microalbuminuria.
Ravipati G; Aronow WS; Ahn C; Alappat RM; McClung JA; Weiss MB
Cardiology; 2008; 109(1):62-5. PubMed ID: 17627110
[TBL] [Abstract][Full Text] [Related]
3. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
[TBL] [Abstract][Full Text] [Related]
4. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure.
Savarese G; Costanzo P; Cleland JG; Vassallo E; Ruggiero D; Rosano G; Perrone-Filardi P
J Am Coll Cardiol; 2013 Jan; 61(2):131-42. PubMed ID: 23219304
[TBL] [Abstract][Full Text] [Related]
5. Incidence of new stroke or new myocardial infarction or death in patients with severe carotid arterial disease treated with and without statins.
Ravipati G; Aronow WS; Ahn C; Channamsetty V; Sekhri V
Am J Cardiol; 2006 Nov; 98(9):1170-1. PubMed ID: 17056320
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations.
Epstein BJ; Gums JG
Ann Pharmacother; 2005 Mar; 39(3):470-80. PubMed ID: 15701766
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
Volpe M; Tocci G; Sciarretta S; Verdecchia P; Trimarco B; Mancia G
J Hypertens; 2009 May; 27(5):941-6. PubMed ID: 19381108
[TBL] [Abstract][Full Text] [Related]
8. Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockers.
Schelleman H; Klungel OH; Witteman JC; Breteler MM; Yazdanpanah M; Danser AH; Hofman A; van Duijn CM; de Boer A; Stricker BH
Eur J Hum Genet; 2007 Apr; 15(4):478-84. PubMed ID: 17299437
[TBL] [Abstract][Full Text] [Related]
9. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Aguilar D; Solomon SD; Køber L; Rouleau JL; Skali H; McMurray JJ; Francis GS; Henis M; O'Connor CM; Diaz R; Belenkov YN; Varshavsky S; Leimberger JD; Velazquez EJ; Califf RM; Pfeffer MA
Circulation; 2004 Sep; 110(12):1572-8. PubMed ID: 15364810
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
11. Primary prevention of myocardial infarction with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertensive patients with rheumatoid arthritis-A nationwide cohort study.
Lin TT; Wu CK; Liao MT; Yang YH; Chen PC; Yeih DF; Lin LY
PLoS One; 2017; 12(12):e0188720. PubMed ID: 29216228
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials.
McAlister FA;
Eur Heart J; 2012 Feb; 33(4):505-14. PubMed ID: 22041554
[TBL] [Abstract][Full Text] [Related]
13. [The clinical usefulness of RAAS inhibitors in hypertensive patients].
Yamaguchi K; Sata M
Nihon Rinsho; 2012 Sep; 70(9):1571-6. PubMed ID: 23012805
[TBL] [Abstract][Full Text] [Related]
14. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.
Bangalore S; Messerli FH; Cohen JD; Bacher PH; Sleight P; Mancia G; Kowey P; Zhou Q; Champion A; Pepine CJ;
Am Heart J; 2008 Aug; 156(2):241-7. PubMed ID: 18657652
[TBL] [Abstract][Full Text] [Related]
15. ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure - A network meta-analysis.
Ricci F; Di Castelnuovo A; Savarese G; Perrone Filardi P; De Caterina R
Int J Cardiol; 2016 Aug; 217():128-34. PubMed ID: 27179902
[TBL] [Abstract][Full Text] [Related]
16. Risk of acute myocardial infarction, stroke, or death in patients initiating olmesartan or other angiotensin receptor blockers - a cohort study using the Clinical Practice Research Datalink.
Zhou EH; Gelperin K; Levenson MS; Rose M; Hsueh YH; Graham DJ
Pharmacoepidemiol Drug Saf; 2014 Apr; 23(4):340-7. PubMed ID: 24285502
[TBL] [Abstract][Full Text] [Related]
17. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
Kenchaiah S; Davis BR; Braunwald E; Rouleau JL; Dagenais GR; Sussex B; Steingart RM; Brown EJ; Lamas GA; Gordon D; Bernstein V; Pfeffer MA;
Am Heart J; 2004 Aug; 148(2):356-64. PubMed ID: 15309009
[TBL] [Abstract][Full Text] [Related]
18. Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or beta-blocker use and the risk of myocardial infarction and stroke.
Schelleman H; Klungel OH; Witteman JC; Breteler MM; Hofman A; van Duijn CM; de Boer A; Stricker BH
Pharmacogenomics J; 2008 Dec; 8(6):400-7. PubMed ID: 18347611
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and the risk of major adverse cardiac events in patients with diabetes and prior stroke: a nationwide study.
Shih CJ; Chen HT; Chao PW; Kuo SC; Li SY; Yang CY; Tarng DC; Ou SM; Chen YT
J Hypertens; 2016 Mar; 34(3):567-74; discussion 575. PubMed ID: 26703918
[TBL] [Abstract][Full Text] [Related]
20. [The effect of ARB on prevention of atherosclerosis].
Aoyama T; Minatoguchi S
Nihon Rinsho; 2011 Jan; 69(1):92-9. PubMed ID: 21226267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
